JTI Philippines Moves to New Office in Bonifacio Global City

JTI by 2FIRSTS.ai
Oct.31.2023
JTI Philippines Moves to New Office in Bonifacio Global City
JTI Philippines subsidiary has relocated to a new office in Bonifacio Global City, officiated by CEO Masamichi Terabatake.

According to reports, JTI's subsidiary in the Philippines has relocated to a new office in Bonifacio Global City.


Masamichi Terabatake, President and CEO of the JT Group, presided over the official inauguration ceremony of the new office, located on the 11th and 12th floors of the Ore Central Tower, at the corner of 31st Street and 9th Avenue.


In his speech, Masamichi Terahata stated that the new office is a symbol of JTI's success and also a recognition of the potential of the Philippine market, especially its people.


Japanese Ambassador to the Philippines, Koshikawa Kazuhiko, expressed that the opening of JTI's new office in the Philippines is another milestone for the company and a strong show of confidence in the country. Despite the prevailing pandemic, JTI remains committed to creating employment opportunities and supporting national development.


John Freda, General Manager of JTI Philippines, stated that this office is not just a new physical space, but rather a place that promotes team collaboration and encourages employees to give their best effort.


In addition, JTI has established a global business service processing office in McKinley West, with over 600 employees. They also have production facilities in Malvar, Rosario, and other places, with nearly 900 employees.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s National Health Insurance Service (NHIS) has again lost on appeal in its damages lawsuit against KT&G, Philip Morris Korea and BAT Korea, seeking ₩53.3 billion (about $36.244 million).
Jan.15 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11
Australian Border Force: Illegal tobacco and vaping products worth A$1 billion in tax revenue gap intercepted in Q2 2025
Australian Border Force: Illegal tobacco and vaping products worth A$1 billion in tax revenue gap intercepted in Q2 2025
Australian Border Force intercepts over $1 billion worth of illegal tobacco and e-cigarettes, totaling 467+ tons. Leading enforcement against smuggling.
Feb.05 by 2FIRSTS.ai
Over 160 organizations urge Formula 1 to end all tobacco sponsorships, including nicotine pouches
Over 160 organizations urge Formula 1 to end all tobacco sponsorships, including nicotine pouches
On March 4, 2026, more than 160 public interest organizations worldwide sent a letter to Formula 1 urging it to expand its 2006 prohibition on cigarette sponsorships to include nicotine pouches and other tobacco products. The letter states that Philip Morris International sponsors Ferrari to promote ZYN pouches, while British American Tobacco sponsors McLaren with its Velo brand, with logos displayed on cars and drivers’ race suits and promoted on social media.
Mar.06 by 2FIRSTS.ai
Philippines DTI Floats Blanket Ban on Open-Pod Vapes and E-Liquids, Seeks Public Input
Philippines DTI Floats Blanket Ban on Open-Pod Vapes and E-Liquids, Seeks Public Input
Philippines’ Department of Trade and Industry (DTI) is inviting stakeholder feedback on a draft Department Administrative Order (DAO) that would impose a blanket ban on open vape pods and e-liquids—covering use, manufacturing, importation, and distribution.
Jan.29 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11